{"disease":{"id":"squamous-cell-carcinoma-mouth","name":"squamous cell carcinoma mouth"},"drugs":{"marketed":[{"drug_id":"cetuximab","indication_name":"Squamous cell carcinoma of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"erbitux","indication_name":"Squamous cell carcinoma of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04333537","title":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":686,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT01465776","title":"Freeze-Dried Black Raspberries in Treating Patients With Oral Squamous Cell Cancer Undergoing Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Amit Agrawal","has_results":false},{"nct_id":"NCT03575598","title":"Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03993353","title":"Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"University of California, San Diego","has_results":true},{"nct_id":"NCT02993991","title":"Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University Health Network, Toronto","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}